Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

November 2020
Generics
Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry

Additional copies are available from:
Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

November 2020
Generics
TABLE OF CONTENTS

I. INTRODUCTION ............................................................................................................. 1
II. BACKGROUND ............................................................................................................... 2
III. MEETING TYPES ........................................................................................................... 3
    A. Product Development Meetings .......................................................................................... 3
    B. Pre-Submission Meetings ...................................................................................................... 4
    C. Mid-Review-Cycle Meetings .................................................................................................. 5
IV. GDUFA II PERFORMANCE GOALS ........................................................................... 6
    A. Performance Goals for Product Development Meetings ....................................................... 6
    B. Performance Goals for Pre-Submission Meetings ................................................................. 6
    C. Performance Goals for MRCMs ............................................................................................. 7
V. MEETING REQUESTS FOR PRODUCT DEVELOPMENT AND PRE-SUBMISSION MEETINGS ......................................................................................................... 7
VI. ASSESSING MEETING REQUESTS FOR PRODUCT DEVELOPMENT AND PRE-SUBMISSION MEETINGS ......................................................................................... 8
    A. Meeting Request Denied ........................................................................................................ 8
    B. Meeting Request Granted ..................................................................................................... 8
VII. RESCHEDULING AND CANCELING PRODUCT DEVELOPMENT AND PRE-SUBMISSION MEETINGS ........................................................................................................... 9
    A. Rescheduled Meetings ......................................................................................................... 9
    B. Canceled Meetings ............................................................................................................. 10
VIII. MEETING PACKAGE CONTENT AND SUBMISSION FOR PRODUCT DEVELOPMENT AND PRE-SUBMISSION MEETINGS ................................................................. 10
    A. Timing of Submission ............................................................................................................. 11
    B. Where and How Many Copies of Meeting Packages To Send ............................................. 11
    C. Meeting Package Content .................................................................................................... 11
IX. PRE-MEETINGS AND COMMUNICATIONS WITH PROSPECTIVE APPLICANTS FOR PRODUCT DEVELOPMENT AND PRE-SUBMISSION MEETINGS ........................................... 12
X. PROCEDURES FOR CONDUCT OF MEETINGS .............................................................. 13
    A. Introductions and Agenda ................................................................................................. 13
    B. End of Meeting Summary .................................................................................................. 13
    C. Presentations ...................................................................................................................... 14
Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry¹

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA office responsible for this guidance as listed on the title page.

I. INTRODUCTION

This guidance describes an enhanced pathway for discussions between FDA and a prospective applicant preparing to submit to FDA or an applicant that has submitted to FDA an abbreviated new drug application (ANDA) for a complex product, as defined in this guidance. Specifically, this guidance provides information on requesting and conducting product development meetings, pre-submission meetings, and mid-review-cycle meetings with FDA.

This guidance reflects a unified approach to all formal meetings between FDA and ANDA applicants or prospective ANDA applicants for complex products.²,³ This guidance will assist ANDA applicants and prospective ANDA applicants in generating and submitting to FDA a meeting request and the associated meeting package for complex products, as defined in this guidance, to be submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C 355(j)) and as contemplated in the reauthorization of the Generic Drug User Fee Amendments for Fiscal Years (FYs) 2018-2022 (GDUFA II).⁴

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of

¹ This guidance has been prepared by the Office of Generic Drugs in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.

² For purposes of this guidance, formal meeting includes any meeting that is requested by a prospective ANDA applicant or ANDA applicant following the request procedures provided in this guidance as well as any meeting offered by the agency following the procedures in this guidance and includes meetings conducted in any format.

³ This guidance uses the term ANDA applicant when discussing meetings that occur after an ANDA is received (i.e., the mid-review-cycle meeting) and the term prospective ANDA applicant when discussing meetings that occur before an ANDA is received (i.e., the product development and pre-submission meetings).

⁴ Generic Drug User Fee Amendments of 2017, Title III, FDA Reauthorization Act of 2017 (Public Law 115-52).
the word *should* in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND

As part of GDUFA II, FDA committed to developing a program to assist ANDA applicants and prospective ANDA applicants of complex products before the submission of an ANDA to FDA. As stated in the GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2018-2022 (GDUFA II Goals or Commitment Letter), this pre-ANDA program is intended to:

... clarify regulatory expectations for prospective applicants early in product development, assist applicants to develop more complete submissions, promote a more efficient and effective ANDA review process, and reduce the number of review cycles required to obtain ANDA approval, particularly for [complex products].

As defined in the GDUFA II Commitment Letter, complex products are:

1. Products with complex active ingredients (e.g., peptides, polymeric compounds, complex mixtures of [active pharmaceutical ingredients], naturally sourced ingredients); complex formulations (e.g., liposomes, colloids); complex routes of delivery (e.g., locally acting drugs such as dermatological products and complex ophthalmological products and otic dosage forms that are formulated as suspensions, emulsions, or gels); or complex dosage forms (e.g., transdermals, metered dose inhalers, extended-release injectables);

2. Complex drug-device combination products (e.g., auto-injectors, metered dose inhalers); and

3. Other products where complexity or uncertainty concerning the approval pathway or possible alternative approach would benefit from early scientific engagement.

To facilitate development of complex products that may be submitted in an ANDA, FDA and industry agreed to a series of meetings between ANDA applicants or prospective ANDA applicants and FDA to discuss the proposed complex product and support submission of a high-quality, approvable ANDA.

---


6 *Applicant* is defined as “any person who submits an…ANDA…under this part to obtain FDA approval of a new drug and any person who owns an approved…ANDA.” 21 CFR 314.3(b). Although only applicants can request meetings under the pre-ANDA program (GDUFA II Commitment Letter at 14), an applicant may include other relevant entities in the meeting, e.g., consultants or drug master file holders.

7 GDUFA II Commitment Letter at 14.

8 Ibid. at 25.
In addition to developing a robust pre-ANDA program, FDA agreed to respond to requests for and conduct meetings related to the development of complex products submitted on or after October 1, 2017, within specific time frames. These GDUFA II performance goals are described further in section IV of this guidance.

III. MEETING TYPES

A. Product Development Meetings

Product development meetings for complex products that may be submitted in an ANDA provide for discussion of specific scientific issues or questions (e.g., a proposed study design, alternative approach, or additional study expectations), in which FDA will provide targeted advice regarding an ongoing ANDA development program. To engage in a substantive discussion, FDA expects that the prospective ANDA applicant has enough knowledge of the complex product to allow FDA to provide appropriate feedback that will advance product development early in the process (e.g., the prospective ANDA applicant has generated its own data to be discussed). FDA anticipates that some prospective ANDA applicants of complex products may request more than one product development meeting. If, following a product development meeting, a prospective ANDA applicant is seeking further clarification or has new question related to what was discussed at the meeting, we recommend that the applicant submit such a request, with any new information or data, in a controlled correspondence for FDA’s review. If the prospective ANDA applicant has new information, data, or questions for Agency input that will not be adequately addressed in a controlled correspondence, the prospective ANDA applicant may request an additional product development meeting. The Agency will determine whether to grant the subsequent product development meeting based on the content of the meeting request and meeting package. FDA recommends that the prospective ANDA applicant submit no more than one request for a product development meeting for the specific complex product per year.

The GDUFA II Commitment Letter identifies when a product development meeting will and when a product development meeting may be granted. Specifically, a product development meeting will be granted if, in FDA’s judgment, the requested meeting concerns development of a complex product for which FDA has not issued: (1) a product-specific guidance, or (2) an alternative equivalence evaluation (i.e., change in study type, such as clinical to in vitro) for a complex product for which FDA has issued a product-specific guidance. Additionally, a product development meeting may be granted if the meeting concerns complex product development issues other than those identified above (e.g., FDA has developed a product-specific guidance

---

9 FDA has received, responded to, and granted certain pre-ANDA meeting requests for products that do not fit within the definition of a complex product as defined in the GDUFA II Commitment Letter and as used in this guidance. The recommendations in this guidance and the performance goals only apply to meeting requests for complex products that may be submitted in an ANDA on or after October 1, 2017. Meeting requests for products that do not fit within the scope of this guidance will be granted based on the workload and availability of staff and the anticipated value to the ANDA review process.

10 GDUFA II Commitment Letter at 27.

11 Ibid. at 15.
and the prospective ANDA applicant is not proposing an alternative equivalence evaluation),
dependent on available resources.

Consistent with Commitment Letter, in addition to demonstrating that the proposed product
development falls within the scope outlined above, prospective ANDA applicants should ensure
all of the following criteria are met so FDA will grant the product development meeting:

1. The prospective ANDA applicant submits a complete meeting package, including any
data generated and specific proposals for product development (e.g., details regarding the
proposed product development plan, such as an alternative study design, and sufficient
justification to support the proposal), as applicable.

2. A controlled correspondence would not adequately address the prospective ANDA
applicant’s questions.

3. A product development meeting would significantly improve ANDA review efficiency
(e.g., ultimately decrease the number of review cycles for the application).12

B. Pre-Submission Meetings

Pre-submission meetings for complex products provide an opportunity for prospective ANDA
applicants to discuss and explain the format and content of the ANDA to be submitted (e.g., data
to support equivalence claims, types of data that will be contained in the ANDA).13 The pre-
submission meeting does not include substantive review of summary data or full study reports,
but FDA will identify items or information that should be clarified before submission of the
ANDA. The pre-submission meeting is not an opportunity to determine whether the application
is acceptable for receipt.14 FDA anticipates that the pre-submission meeting will take place
approximately 6 months before submission of the ANDA. FDA attendees at the pre-submission
meeting will generally include staff that attended the product development meeting, if held, and
additional review staff that may review the ANDA once received.

Prospective ANDA applicants of complex products may request a pre-submission meeting
whether or not they had a product development meeting. Note that a prospective ANDA
applicant that had a product development meeting or received written responses from FDA is not
obligated to request the pre-submission meeting. FDA will generally grant pre-submission
meetings for prospective ANDA applicants that have had a product development meeting or
received a written response. FDA may grant a pre-submission meeting to a prospective ANDA
applicant of a complex product that did not have a product development meeting if, in FDA’s
judgment, the pre-submission meeting would improve review efficiency.

---

12 Ibid. at 15.
13 Ibid. at 27.
14 For example, the prospective ANDA applicant should not request or expect guidance on whether certain
components needed for receipt consideration may be omitted from the ANDA.
C. Mid-Review-Cycle Meetings

A mid-review-cycle meeting (MRCM) for a complex product is held only during the first review cycle with ANDA applicants that have participated in a prior product development or pre-submission meeting. The MRCM will generally take place 30 days after the mid-point of the review cycle.\(^{15}\) The MRCM affords an opportunity for FDA to:

1. Convey significant issues or concerns that were identified during review of the ANDA.
2. Ask the applicant clarifying questions about its submission.
3. Outline recommended next steps to the applicant.

The Regulatory Project Manager (RPM) assigned to the ANDA will contact an eligible applicant to schedule the MRCM meeting (held by teleconference for 30 minutes). ANDA applicants that participated in a product development and/or pre-submission meeting should not request a mid-review-cycle meeting; the RPM will initiate scheduling this meeting for eligible applicants. Because these meetings are optional, the applicant may decline the MRCM. If an eligible applicant does wish to decline the mid-review-cycle meeting, FDA recommends that the applicant submit a letter to the ANDA file indicating its decision.

During the mid-review-cycle meeting, the RPM and certain members of the review team, as appropriate, considering any deficiencies or requests for clarification communicated to the applicant, will participate in the teleconference. FDA will provide the applicant with an update on the status of the review of its application.\(^{16}\) An agenda will be provided to the applicant by the RPM. The agenda will generally consist of possible deficiencies found by a discipline reviewer and/or review team for its portion of the pending application at the conclusion of the discipline review (i.e., the content of a Discipline Review Letter (DRL)).\(^{17}\) If a DRL has already been issued, the agenda will generally provide for a status update. FDA intends to send the agenda to the applicant 7 calendar days before the teleconference.

---

\(^{15}\) The GDUFA II Commitment Letter states that after the last key discipline has issued its information request (IR) and/or discipline review letter (DRL) the mid-review-cycle meeting will be scheduled (at 26). Because FDA may issue an IR or DRL at any time during the review, consequently, FDA intends to conduct the mid-review-cycle meeting at a specific time during the review cycle, generally 30 days after the mid-point of the review cycle.

\(^{16}\) GDUFA II Commitment Letter at 17.

\(^{17}\) Ibid. at 25.
IV. GDUFA II PERFORMANCE GOALS

As indicated in section II, FDA committed to meet certain performance review goals associated with the pre-ANDA meetings for complex products described in this guidance. The goals described below only apply to meetings related to complex products under GDUFA II (i.e., requests submitted on or after October 1, 2017, and subject to the criteria described in this guidance).

A. Performance Goals for Product Development Meetings

Per the Commitment Letter, FDA will grant or deny 90 percent of product development meeting requests for complex products under GDUFA II within 14 calendar days of receipt in FYs 2020, 2021, and 2022.18

FDA will conduct product development meetings for complex products pursuant to the following performance goals:

1. In FY 2020, 80 percent of the meetings will be conducted within 120 calendar days of granting the request.

2. In FYs 2021 and 2022, 90 percent of the meetings will be conducted within 120 calendar days of granting the request.19

FDA can also meet the product development meeting goal by providing meaningful written responses to the prospective ANDA applicant, within the applicable goal date, that address relevant drug development and/or regulatory issues.20

B. Performance Goals for Pre-Submission Meetings

FDA will grant or deny 90 percent of pre-submission meeting requests for complex products under GDUFA II within 14 calendar days of receipt in FYs 2020, 2021, and 2022.21

FDA will conduct pre-submission meetings for complex products pursuant to the following performance goals:

1. In FY 2020, 80 percent of the meetings will be conducted within 120 calendar days of granting the request.

18 Ibid. at 16.
19 Ibid.
20 Ibid.
21 Ibid. at 16-17.
2. In FYs 2021 and 2022, 90 percent of the meetings will be conducted within 120 calendar days of granting the request.22

C. Performance Goals for MRCMs

There is no specified performance review goal associated with the MRCMs. As stated in section III.C, in general FDA intends to conduct these meetings 30 days after the mid-point of the review cycle. The date for the MRCM is subject to change if, for example, the applicant submits an unsolicited amendment.23

V. MEETING REQUESTS FOR PRODUCT DEVELOPMENT AND PRE-SUBMISSION MEETINGS

A request for a product development or pre-submission meeting for complex products that may be submitted in an ANDA should be sent electronically through the CDER Direct NextGen Collaboration Portal.24, 25 A request for a pre-submission meeting should clearly indicate whether the prospective applicant had a product development meeting with FDA. If no product development meeting was held, the prospective applicant should explain why a pre-submission meeting should be granted. A product development or pre-submission meeting request should include the following information:

1. Pre-assigned ANDA number.26

2. Meeting type being requested (i.e., product development or pre-submission).

3. Reference listed drug (RLD) and its application number.

4. Dosage form, route of administration, and strength.

5. A statement indicating whether the submission is being made by the prospective ANDA applicant or by a U.S. agent on behalf of the prospective ANDA applicant.

22 Ibid.

23 See guidance for industry ANDA Submissions – Amendments to Abbreviated New Drug Applications Under GDUFA.

24 Applicants should not submit meeting requests for the MRCM because the RPM will contact the applicant to schedule the meeting. See section III.C of this guidance.


26 See information regarding requesting a pre-assigned application number available on FDA’s website at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm114027.htm.
6. Contact person for the meeting (i.e., the person submitting the meeting request), with their title and affiliation, secure email address, and phone number. This is the person with whom FDA will communicate about the meeting.

7. The meeting package (see section VIII of this guidance), which should be received at the time of the meeting request for both product development and pre-submission meetings.

If FDA determines that the meeting request does not contain the information specified in this section, the request will not be considered to be submitted for purposes of GDUFA II performance goals.

VI. ASSESSING MEETING REQUESTS FOR PRODUCT DEVELOPMENT AND PRE-SUBMISSION MEETINGS

The Office of Generic Drugs’ (OGD’s) Office of Research Standards (ORS), with input from the Office of Pharmaceutical Quality (OPQ), will determine whether to grant a product development and/or pre-submission meeting request for complex products that may be submitted in an ANDA, and a response will be provided to the prospective applicant by granting or denying the meeting request pursuant to the performance goals stated in the GDUFA II Commitment Letter (see section IV).

A. Meeting Request Denied

If a request for a product development or pre-submission meeting for a complex product is denied, written notification to the prospective applicant will include an explanation of the reason for the denial. Denials of meeting requests submitted in conformity with the GDUFA II performance goals will be based on a substantive reason, not merely on the absence of a minor element of the meeting request or meeting package items. For example, a product development or pre-submission meeting request may be denied because the product does not meet the criteria for a complex product as provided in section II of this guidance or because a meeting is premature for the stage of product development in light of the insufficiency of the data generated. A subsequent request to schedule the product development or pre-submission meeting will be considered as a new request.

B. Meeting Request Granted

If a request for a product development or pre-submission meeting is granted, FDA will provide notification to the prospective applicant of the decision by email. If FDA plans to provide a written response instead, FDA will advise the prospective applicant that a written response is forthcoming. If FDA plans to hold a meeting, FDA will schedule the meeting by determining the

27 Secure email between CDER and ANDA applicants and prospective ANDA applicants is useful for informal communications when confidential information (e.g., trade secrets or patient information) may be included in the message. Secure email should not be used for formal regulatory submissions. For more information on establishing a secure email link with CDER, please contact SecureEmail@fda.hhs.gov.
date, time, length, place, and expected FDA participants. All of the scheduling information will be forwarded to the prospective applicant as soon as possible following notification that the meeting request has been granted, and the meeting will be scheduled within the specified GDUFA II performance goals (see section IV) of this guidance.

VII. RESCHEDULING AND CANCELING PRODUCT DEVELOPMENT AND PRE-SUBMISSION MEETINGS

Circumstances may arise that necessitate the rescheduling or canceling of a meeting. For product development and pre-submission meetings, FDA will determine whether the meeting should be rescheduled or canceled, depending on the specific circumstances. Prospective applicants and FDA should take reasonable steps to avoid rescheduling and canceling meetings (unless the meeting is no longer necessary). For example, if an attendee becomes unavailable, a substitute can be identified, or comments on the topic that the attendee would have addressed can be forwarded to the prospective applicant following the meeting.

A. Rescheduled Meetings

If FDA determines that a meeting needs to be rescheduled, FDA will reschedule it as soon as possible after the original date. A new meeting request should not be submitted and new time frames should not be set for rescheduled meetings.

A meeting may be rescheduled if, for example:

1. The review team determines that additional information is needed from the prospective ANDA applicant to address the prospective ANDA applicant’s questions.

2. Essential attendees are no longer available for the scheduled date and time because of an emergency.

3. Attendance by additional FDA offices not originally anticipated or requested by the prospective ANDA applicant is critical and the offices’ availability precludes holding the meeting on the original date.

4. There is a regulatory policy issue that is yet to be resolved that may affect the response to the prospective ANDA applicant’s questions.

5. The Federal Government is closed or opening is delayed due to inclement weather, emergency, or other reason.

---

28 In general, the subsections below apply only to product development and pre-submission meetings for complex products. However, the mid-review-cycle meeting for complex products may also be rescheduled or canceled. If a mid-review-cycle meeting is rescheduled, FDA will seek to reschedule the meeting within 14 calendar days of the originally scheduled date.
If a prospective ANDA applicant requests that a product development or pre-submission meeting be rescheduled, FDA will make every effort to ensure the meeting occurs within the goal date (see section IV). If FDA is unable to reschedule the meeting within the original goal date, FDA will still consider the performance goal met if the Agency is able to schedule and conduct the meeting within a 30-day extension added on to the original goal date.

B. Canceled Meetings

If a meeting is canceled, a subsequent request to schedule a meeting will be considered a new request.

A product development or pre-submission meeting may be canceled if, for example:

1. The prospective ANDA applicant withdraws the meeting request.
2. The prospective ANDA applicant determines its questions have been adequately answered by the preliminary written comments.
3. FDA issues product-specific guidance on establishing bioequivalence to the RLD that is the basis of submission for the prospective ANDA applicant.29

If a prospective ANDA applicant cancels a product development or pre-submission meeting, FDA will count the performance goal as met. If FDA cancels the meeting, the meeting request will not be counted for performance goal purposes.

VIII. MEETING PACKAGE CONTENT AND SUBMISSION FOR PRODUCT DEVELOPMENT AND PRE-SUBMISSION MEETINGS30

Pre-meeting preparation is critical for achieving a productive discussion or exchange of information at the product development and pre-submission meetings for complex products that may be submitted in an ANDA. Preparing the meeting package should help the prospective ANDA applicant focus on describing its principal areas of interest. The meeting package should provide information relevant to the discussion topics and enable FDA to prepare adequately for the meeting. The meeting package should clearly indicate that the prospective applicant is requesting a product development or pre-submission meeting and should include adequate information for FDA to assess the potential utility of the meeting and to identify the appropriate staff that should attend the meeting. A package for a pre-submission meeting should clearly indicate whether the prospective applicant had a product development meeting with FDA. If no

29 FDA publishes new and revised product-specific guidances describing the Agency’s current recommendations for demonstrating bioequivalence and certain other approval requirements. Please check for the availability of new and revised product-specific guidances in the Federal Register and on the FDA website at the following address: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm.

30 In general, the subsections below do not apply to the MRCM for complex product ANDAs. As stated in this guidance, FDA will schedule and prepare the agenda for the MRCM for any complex product ANDA for which there was a product development or pre-submission meeting.
product development meeting was held, the prospective applicant should explain why a pre-submission meeting should be granted.

A. Timing of Submission

The meeting package both for a product development and a pre-submission meeting for a complex product should be submitted to OGD so that it is received concurrently with the meeting request.

B. Where and How Many Copies of Meeting Packages To Send

Both the product development and pre-submission meeting packages should be sent electronically to the CDER Direct NextGen Collaboration Portal with the meeting request. It is not necessary to submit any paper copies of the meeting package.

C. Meeting Package Content

The meeting package should provide information relevant to the product, development stage, and meeting type requested, in addition to any supplementary information needed to develop responses to issues raised by the prospective ANDA applicant or FDA. The meeting package should contain sufficient detail to meet the intended meeting objectives.

To facilitate FDA review, the meeting package content should be organized according to the proposed agenda. The meeting package should be a sequentially paginated document (individual sections can be numbered separately, as long as there is an overall pagination covering the whole submission) with a table of contents, appropriate indices, appendices, cross-references, and tabs differentiating sections. Meeting packages generally should include the following information:

1. Pre-assigned ANDA number.
2. Established name.
3. Chemical structure.
4. RLD and application number.
5. Proposed indication(s).
6. Dosage form, route of administration, and dosing regimen (frequency and duration).
7. A background section that includes the following:
   a. A brief history of the development program.
   b. The status of product development.
8. A brief statement indicating how the product meets the criteria for a complex product (see section II).
9. A brief statement of the purpose and objectives of the meeting. This statement should include a brief background of the issues underlying the agenda.

10. A list of all individuals, with their titles and affiliations, who will attend the requested meeting from the prospective ANDA applicant’s organization, including consultants and interpreters.

11. Suggested dates and times (e.g., morning or afternoon) for the meeting that are within the time frame of the meeting type being requested (i.e., within a period of 120 days after the date the meeting may be granted (see section IV)). Nonavailability dates and times should also be included.

12. The proposed format of the meeting (i.e., written response, face-to-face, or teleconference).

13. A proposed agenda, including estimated times needed for discussing each agenda item (note that the meetings are generally only one hour in length).

14. A list of questions for discussion, grouped by discipline, as applicable, with each question clearly numbered (e.g., 1, 2, 3 without subquestions). For each question, there should be a brief explanation of the context and purpose of the question and any supporting rationale or data, as applicable. The prospective ANDA applicant should consider the duration of the proposed meeting when determining the proposed questions. The package should be organized such that following a summary list of all questions, each question is followed by the corresponding supporting justification, rationale, or data, as applicable, followed by the next question.

15. Data to support discussion organized by discipline and question. The level of detail should be appropriate to the meeting type requested and the product development stage (e.g., if an approach or alternative approach is proposed for establishing equivalence, sufficient rationale together with at least preliminary data should be provided).

IX. PRE-MEETINGS AND COMMUNICATIONS WITH PROSPECTIVE APPLICANTS FOR PRODUCT DEVELOPMENT AND PRE-SUBMISSION MEETINGS

Before the product development or pre-submission meeting for a complex product, FDA holds internal meetings to discuss meeting packages and gain internal alignment on the initial responses to a prospective ANDA applicant’s questions. For a product development meeting, if FDA is not providing a written response to the prospective ANDA applicant, FDA intends to

31 In general, preliminary written comments will not be provided in advance of a MRCM, as FDA sets the agenda for this meeting.
provide preliminary written comments to the prospective ANDA applicant’s point of contact 5 calendar days before the meeting. If FDA determines it is appropriate to provide preliminary written comments before a pre-submission meeting, any such comments will be sent by email to the prospective ANDA applicant’s designated point of contact identified in the original meeting request 5 calendar days before the meeting.

Communications before the meeting between prospective ANDA applicants and FDA, including preliminary written comments, can serve as a foundation for discussion or as the final meeting responses. Nevertheless, preliminary written comments should not be construed as final unless there is agreement between the prospective ANDA applicant and FDA that additional discussion is not necessary for any question (i.e., when the meeting is canceled because the prospective ANDA applicant is satisfied with FDA’s preliminary written comments), or the prospective ANDA applicant and FDA agree a particular question is considered resolved, allowing extra time for discussion of other questions during the meeting. After receiving the preliminary written comments, the prospective applicant should provide an updated agenda with its list of questions for discussion in order of priority, no later than 48 hours before the scheduled meeting. Preliminary written comments communicated by FDA should not generate the submission of new questions, and new questions will not be entertained at the meeting.

X. PROCEDURES FOR CONDUCT OF MEETINGS

A. Introductions and Agenda

Product development and pre-submission meetings for complex products will be chaired by an FDA staff member, generally the ORS director or designee, and will begin with introductions and a statement of the agenda. In general, the meeting participants will discuss the questions posed and the data provided by the prospective ANDA applicant to assist its complex product development program.

The RPM assigned to the ANDA will chair the MRCM. As explained in section III.C, the agenda will be provided by FDA and will generally consist of a status update and possible deficiencies identified by a discipline reviewer and/or review team at the conclusion of the discipline review or will provide for a discussion of deficiencies that have been communicated to the prospective ANDA applicant before the meeting.

B. End of Meeting Summary

Before the end of the meeting, FDA attendees and the prospective ANDA applicant or ANDA applicant attendees should summarize the important discussion points, agreements, clarifications,

32 GDUFA II Commitment Letter at 16.
33 Ibid. at 17.
34 In general, FDA attendees may include, as applicable, additional staff from CDER’s OGD, OPQ, Office of Surveillance and Epidemiology, and Office of New Drugs. Center for Devices and Radiological Health staff may also attend if the complex product has a device component.
and action items. Generally, the prospective ANDA applicant or ANDA applicant will be asked to present the summary to ensure that there is mutual understanding of meeting outcomes and action items. FDA staff can add or further clarify any important points not covered in the summary, and these items can be added to the meeting minutes. The summary can be done at the end of the meeting or after the discussion of each question.

C. Presentations

Presentations by prospective ANDA applicants or ANDA applicants are not generally needed because the information necessary for review and discussion should be part of the meeting package. If a prospective ANDA applicant or ANDA applicant plans to make a presentation, the presentation should be discussed ahead of time with the FDA point of contact to ensure that FDA has the presentation materials ahead of the meeting, if possible. All presentations should be kept brief to maximize the time available for discussion.

The length of the meeting will not be increased to accommodate a presentation. If a presentation contains more than a small amount of content distinct from clarifications or explanations of previous data, or contains data that were not included in the original meeting package submitted to FDA for review, FDA staff may not be able to provide comments on the new information.

FDA does not expect that the applicant attendees of the MRCM will provide any presentations.

XI. DOCUMENTATION AND MEETING MINUTES

Documentation of meeting outcomes, agreements and disagreements, issues for further discussion, and action items is critical to ensuring that this information is preserved for meeting attendees and for future reference. FDA minutes are the official record of the meeting. FDA will issue the official, finalized minutes to the prospective ANDA applicant within 30 days of the product development or pre-submission meeting. FDA intends to issue minutes for the MRCM within 30 days of the meeting.

XII. RESOLUTION OF DISPUTE ABOUT MEETING MINUTES

On occasion, there may be disputes regarding the accuracy and sufficiency of the minutes of a product development meeting, pre-submission meeting, or the MRCM. A prospective ANDA applicant or ANDA applicant requesting additional clarification of the meeting minutes issued by FDA should contact the assigned FDA point of contact. FDA recommends that the prospective ANDA applicant or ANDA applicant submit its concerns about the meeting minutes in writing to FDA within 10 calendar days of receipt of the official meeting minutes. This process addresses issues with the meeting minutes only. If a prospective ANDA applicant needs to discuss additional issues that were not addressed at the product development or pre-submission meeting, the prospective ANDA applicant should submit a controlled correspondence or a new meeting

\[\text{35 GDUFA II Commitment Letter at 16-17.}\]
request. If an ANDA applicant needs to discuss additional issues that were not addressed at the MRCM, the ANDA applicant should contact the RPM.

If, after following up as described above, there are still significant differences in the prospective ANDA applicant’s or ANDA applicant’s and FDA’s understanding of the content of the official meeting minutes, the prospective ANDA applicant or ANDA applicant should notify FDA in writing with respect to specific disagreements. The prospective ANDA applicant or ANDA applicant should submit the correspondence to its application or, if there is no application, submit a letter to the division director of the responsible division, with a copy to the FDA point of contact describing the concern.

The prospective ANDA applicant’s or ANDA applicant’s concerns will be taken under consideration by the review division and the office director if the office director was present at the meeting. If the minutes are determined to accurately and sufficiently reflect the meeting discussion, the point of contact will convey this decision to the prospective ANDA applicant or ANDA applicant, and the minutes will stand as the official documentation of the meeting. If, after discussions with the prospective ANDA applicant or ANDA applicant, FDA deems it necessary to change the official minutes, the changes will be documented in an addendum to the official minutes. The addendum will also document any continued objections.36

---

36 Any addendum will be shared with the prospective ANDA applicant or ANDA applicant by FDA.
APPENDIX:

SUMMARY OF SCOPE AND CRITERIA FOR MEETINGS FOR COMPLEX PRODUCTS UNDER GDUFA II

<table>
<thead>
<tr>
<th>Meeting Type</th>
<th>Purpose/Scope</th>
<th>Criteria</th>
<th>Additional Considerations</th>
</tr>
</thead>
</table>
| Product Development  | (a) Development of a complex product for which FDA has not issued product-specific guidance | • Meets the purpose/scope  
• Prospective ANDA applicant submits a complete meeting package  
• Controlled correspondence response would not adequately address the prospective applicant’s questions  
• Product development meeting would significantly improve ANDA review efficiency | • Goal may be met by conducting a meeting or providing a meaningful written response          |
|                      | (b) Alternative equivalence evaluation for a complex product for which FDA has issued a product-specific guidance | • Meets the purpose/scope  
• Prospective ANDA applicant submits a complete meeting package  
• Controlled correspondence response would not adequately address the prospective applicant’s questions  
• Product development meeting would significantly improve ANDA review efficiency | • Goal may be met by conducting a meeting or providing a meaningful written response          |
|                      | (c) Complex product development issues other than those described in (a) and (b) above | • Meets the purpose/scope  
• Prospective ANDA applicant submits a complete meeting package  
• Controlled correspondence response would not adequately address the prospective applicant’s questions  
• Product development meeting would significantly improve ANDA review efficiency | • Granting of meeting is dependent on available resources  
• Goal may be met by conducting a meeting or providing a meaningful written response          |
| Pre-Submission        | Opportunity for prospective ANDA applicants to discuss and explain the format and content of the ANDA to be submitted | • FDA will generally grant a pre-submission meeting request for prospective ANDA applicants that had a product development meeting or received a written response  
• FDA may grant a pre-submission meeting to a prospective ANDA applicant of a complex product that did not have a product development meeting if, in FDA’s judgment, the pre-submission meeting would improve review efficiency | • Prospective ANDA applicant that had a product development meeting or received a written response is not obligated to request a pre-submission meeting |
| Mid-Review-Cycle | Opportunity for FDA to discuss issues identified during review with the applicant | • Held only during the first review cycle with ANDA applicants that have participated in a prior product development or pre-submission meeting | • Mid-review-cycle meeting will be scheduled by FDA; FDA will provide agenda • ANDA applicant that had product development or pre-submission meeting is not obligated to attend (i.e., may decline) mid-review-cycle meeting |